TiVo (TIVO) Forms $14.55 Double Bottom; 4 Analysts Bullish Oramed Pharmaceuticals Inc. (ORMP)

TiVo Corporation (NASDAQ:TIVO) Logo

Among 4 analysts covering Oramed Pharmaceuticals (NASDAQ:ORMP), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Oramed Pharmaceuticals had 9 analyst reports since August 14, 2015 according to SRatingsIntel. The rating was maintained by B. Riley & Co with “Buy” on Monday, December 11. The rating was maintained by H.C. Wainwright on Wednesday, November 22 with “Buy”. The stock of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) has “Outperform” rating given on Thursday, November 19 by FBR Capital. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, December 1 report. The company was upgraded on Friday, August 14 by Zacks. The rating was maintained by H.C. Wainwright on Thursday, October 5 with “Buy”. Rodman & Renshaw initiated the stock with “Buy” rating in Friday, October 2 report. The stock of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) earned “Buy” rating by H.C. Wainwright on Thursday, October 1. See Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) latest ratings:

11/12/2017 Broker: B. Riley & Co Rating: Buy New Target: $20 Maintain
11/12/2017 Broker: FBR Capital Rating: Buy New Target: $20.0
22/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $25.0 Maintain

TiVo Corporation (TIVO) formed double bottom with $13.53 target or 7.00% below today’s $14.55 share price. TiVo Corporation (TIVO) has $1.79B valuation. It closed at $14.55 lastly. It is down 24.65% since April 25, 2017 and is downtrending. It has underperformed by 36.20% the S&P500.

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. The company has market cap of $111.35 million. The Company’s product portfolio includes ORMD-0801, an oral insulin capsule, which has completed Phase IIb clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which has completed Phase Ib clinical trials for the treatment of type 2 diabetes. It currently has negative earnings. The firm operates primarily in Israel.

The stock increased 1.98% or $0.15 during the last trading session, reaching $7.71. About 45,718 shares traded or 85.90% up from the average. Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) has risen 11.98% since April 25, 2017 and is uptrending. It has outperformed by 0.43% the S&P500.

Investors sentiment increased to 2.75 in Q4 2017. Its up 0.75, from 2 in 2017Q3. It improved, as 1 investors sold Oramed Pharmaceuticals Inc. shares while 3 reduced holdings. 4 funds opened positions while 7 raised stakes. 329,110 shares or 28.57% more from 255,973 shares in 2017Q3 were reported. Renaissance Technologies Ltd Llc stated it has 93,500 shares. Bancorp Of Montreal Can holds 2,600 shares or 0% of its portfolio. Jfs Wealth Ltd Liability Company invested in 500 shares. Fin Architects owns 0% invested in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) for 2,750 shares. Wells Fargo Mn holds 10,450 shares. One Trading Limited Partnership holds 0% or 11,477 shares in its portfolio. Royal Commercial Bank Of Canada invested 0% of its portfolio in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). Morgan Stanley accumulated 35,994 shares. Deutsche Comml Bank Ag accumulated 34,608 shares. Pnc Finance Group Inc has 0% invested in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) for 21,200 shares. Bancorp Of America De owns 1,117 shares for 0% of their portfolio. Macquarie Gru Limited reported 3,499 shares. Jpmorgan Chase And Com holds 1,700 shares or 0% of its portfolio. Glenmede Trust Na owns 0% invested in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) for 20,000 shares. Tower Research Capital Limited Com (Trc), a New York-based fund reported 131 shares.

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Institutional Positions Chart